7 . FINANCIAL COST 
You are responsible for the costs of the physician visits, 
hospitalizations, laboratory and diagnostic tests not related to this 
study. There will be no charge for the immunizations, the blood tests 
performed to evaluate the immune response to the injected material and 
the hospitalization for the 23 hour period of observation proposed in 
the trial. 
8. PRIVACY 
Your research and hospital records are confidential. Your name or any 
other personally identifying information will not be used in reports or 
publications resulting form this study. The National Institutes of 
Health, the Food and Drug Administration (FDA), or other authorized 
agencies as well as hospital personnel may inspect your records. A 
qualified representative of the National Cancer Institute and the 
University of Illinois' Institutional Review Board may inspect the 
patient/study records. All efforts will be made to ensure your privacy 
but this cannot be absolutely guaranteed. 
9. NEED FOR EFFECTIVE CONTRACEPTION. 
Participation in this study requires you to practice effective 
contraception. Should contraception be interrupted, or if there is a 
suspicion of pregnancy, you further participation in the study may be 
interrupted at the sole discretion of the Principal Investigator. 
10. PERMISSION FOR POSTMORTEM IN THE EVENT OF DEATH. 
Since this is a new study that may be of benefit of other patients, so as 
to gain the most possible knowledge, in the event of death you agree that a 
postmortem may be performed. 
[370] 
Recombinant DNA Research, Volume 18 
